A multi-institutional study led by investigators at Massachusetts General Hospital (MGH) and Johns Hopkins School of Medicine has found how the abnormal form of tau that accumulates in the neurofibrillary tangles that characterize Alzheimer's disease can disrupt the normal function of brain cells. In their report published in the journal Neuron, the team describes how tau interferes with communication between the nucleus of neurons and the rest of the cell body, called the cytoplasm.
"Communication between the nucleus and the rest of the cell is usually a tightly regulated process," says co-senior author Bradley Hyman, MD, PhD, director of the MGH-based Massachusetts Alzheimer's Disease Research Center. "Our work shows a new way tau might cause brain cells to become impaired. In other systems, disruption of this communication causes cell misfunction and even cell death, so we think this might contribute to neuronal dysfunction and death in Alzheimer's disease as well."
Recent research by Hyman's team had discovered a newly identified biochemical feature of tau - that under circumstances it can form microscopic droplets. A search for other proteins with this property led the investigators to the proteins of the nuclear pore complex - a structure on the nuclear membrane that controls the passage of proteins and RNA between the nucleus and the cytoplasm. They set out to investigate whether and how tau might interact with proteins in the nuclear pore complex, which contains 30 different proteins called nucleoporins that form the channel through which molecules move.
Small molecules can pass freely through the nuclear pore complex, but larger molecules need to be actively transported by interactions between receptor proteins on those molecules and nucleoporins. Whether molecules are moved into or out of the nucleus depends on shuttling of the enzyme RanGTP between the nucleus and the cytoplasm. Problems with nucleocytoplasmic transport in neurons have been reported in several neurodegenerative diseases, as well as in normal aging.
In their experiments in neurons from patients with Alzheimer's disease and in cellular models of tau-based neuropathology, the researchers found that the Alzheimer's-associated form of tau - which is studded with phosphate molecules - directly interacts with an important nucleoporin called Nup98. This interaction led to Nup98's being mislocated into the cytoplasm, where it promoted the aggregation of tau into neurofibrillary tangles. In addition, the nuclei of neurons from Alzheimer's patients took up large test molecules, indicating that the nuclear pore complexes had become leaky. The structures were also reduced in number and unevenly distributed throughout the nuclear membrane
Neurons from mice genetically programmed to develop tau brain tangles also showed similar nuclear pore complex leakage, allowing passage of large dye molecules into the nuclei. Levels of Ran enzymes were depleted from the animals' neuronal nuclei, which also showed changes in shape and structure. Suppressing expression of the abnormal tau gene restored nuclear levels of Ran and levels of Nup98 in the nuclear membrane. Knocking down levels of Nup98 in neurons from these mice restored an appropriate Ran ratio between the nucleus and cytoplasm, showing that tau was the cause of the Ran abnormalities.
"One of the exciting things about these findings is that, if we can block the interaction between tau and the nuclear pore, it might allow existing neurons to become more functional in patients; so one of our next steps will be determining whether or not that is possible" says Hyman, who is the John Penney Professor of Neurology at Harvard Medical School. "The collaboration between groups from across the country - including Johns Hopkins, the Mayo Clinic and the Salk Institute - with each group adding its special expertise, made this work possible."
Jeffrey Rothstein, MD, PhD, director of the Brain Science Institute at Johns Hopkins School of Medicine is the co-senior author of the Neuron paper; co-lead authors are Bahareh Eftekharzadeh, PharmD, PhD, formerly with MGH Neurology and now at Biogen, and J. Gavin Daigle, PhD, formerly at Johns Hopkins and now at Abbvie, Inc. Support for the study includes National Institutes of Health grants P01 NS099114, R01 NS094239, R01 NS099320 and P50 AG005134, and philanthropy from the JBP Foundation.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2018 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."